- Home
- BAFN vs RAPT Comparison
BAFN vs RAPT Comparison
Compare BAFN & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAFN
- RAPT
- Stock Information
- Founded
- BAFN 1999
- RAPT 2015
- Country
- BAFN United States
- RAPT United States
- Employees
- BAFN N/A
- RAPT N/A
- Industry
- BAFN Savings Institutions
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- BAFN Finance
- RAPT Health Care
- Exchange
- BAFN Nasdaq
- RAPT Nasdaq
- Market Cap
- BAFN 55.9M
- RAPT 65.6M
- IPO Year
- BAFN N/A
- RAPT 2019
- Fundamental
- Price
- BAFN $12.98
- RAPT $1.05
- Analyst Decision
- BAFN
- RAPT Hold
- Analyst Count
- BAFN 0
- RAPT 10
- Target Price
- BAFN N/A
- RAPT $5.00
- AVG Volume (30 Days)
- BAFN 8.7K
- RAPT 1.1M
- Earning Date
- BAFN 10-24-2024
- RAPT 11-12-2024
- Dividend Yield
- BAFN 2.37%
- RAPT N/A
- EPS Growth
- BAFN N/A
- RAPT N/A
- EPS
- BAFN 0.73
- RAPT N/A
- Revenue
- BAFN $76,217,000.00
- RAPT N/A
- Revenue This Year
- BAFN N/A
- RAPT N/A
- Revenue Next Year
- BAFN N/A
- RAPT N/A
- P/E Ratio
- BAFN $18.08
- RAPT N/A
- Revenue Growth
- BAFN 7.06
- RAPT N/A
- 52 Week Low
- BAFN $10.15
- RAPT $1.00
- 52 Week High
- BAFN $15.05
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- BAFN 40.68
- RAPT 32.76
- Support Level
- BAFN $13.46
- RAPT $1.31
- Resistance Level
- BAFN $15.05
- RAPT $1.96
- Average True Range (ATR)
- BAFN 0.57
- RAPT 0.34
- MACD
- BAFN -0.05
- RAPT -0.14
- Stochastic Oscillator
- BAFN 32.41
- RAPT 2.16
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a one bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.